PT - JOURNAL ARTICLE AU - Günther, Theresa AU - Schöfbänker, Michael AU - Lorentzen, Eva Ulla AU - Romberg, Marie-Luise AU - Hennies, Marc Tim AU - Neddermeyer, Rieke AU - Müller, Marlin Maybrit AU - Mellmann, Alexander AU - Lenz, Georg AU - Stelljes, Matthias AU - Hrincius, Eike Roman AU - Vollenberg, Richard AU - Ludwig, Stephan AU - Tepasse, Phil-Robin AU - Kühn, Joachim Ewald TI - Variant-specific humoral immune response to SARS-CoV-2 escape mutants arising in clinically severe, prolonged infection AID - 10.1101/2024.01.06.24300890 DP - 2024 Jan 01 TA - medRxiv PG - 2024.01.06.24300890 4099 - http://medrxiv.org/content/early/2024/01/07/2024.01.06.24300890.short 4100 - http://medrxiv.org/content/early/2024/01/07/2024.01.06.24300890.full AB - Neutralising antibodies against the SARS-CoV-2 spike (S) protein are major determinants of protective immunity, though insufficient antibody responses may cause the emergence of escape mutants. We studied the intra-host evolution and the humoral immune response in a B-cell depleted, haemato-oncologic patient experiencing clinically severe, prolonged SARS-CoV-2 infection with a virus of lineage B.1.177.81.Bamlanivimab treatment early in infection was associated with the emergence of the bamlanivimab escape mutation S:S494P. Ten days before virus elimination, additional mutations within the N-terminal domain (NTD) and the receptor binding domain (RBD) of S were observed, of which the triple mutant S:Delta141-4 E484K S494P became dominant. Routine serology revealed no evidence of an antibody response in the patient. A detailed analysis of the variant-specific immune response by pseudotyped virus neutralisation test (pVNT), surrogate VNT (sVNT), and immunoglobulin-capture EIA showed that the onset of an IgM-dominated antibody response coincided with the appearance of escape mutations. The formation of neutralising antibodies against S:Delta141-4 E484K S494P correlated with virus elimination. One year later, the patient experienced clinically mild re-infection with Omicron BA.1.18, which was treated with sotrovimab and resulted in a massive increase of Omicron-reactive antibodies.In conclusion, the onset of an IgM-dominated endogenous immune response in an immunocompromised patient coincided with the appearance of additional mutations in the NTD and RBD of S in a bamlanivimab-resistant virus. Although virus elimination was ultimately achieved, this humoral immune response escaped detection by routine diagnosis and created a situation temporarily favouring the emergence of escape variants with known epidemiological relevance.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe Institute of Virology is part of the Virus Alliance North Rhine-Westphalia, which is supported by the Ministry of Culture and Science, NRW, Germany. The funders played no role in study design, data collection, analysis and interpretation, the preparation of the manuscript, or the decision to publish.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The patient presented in our study has given informed consent to data collection and publication. The ethics committee of the Aerztekammer Westfalen-Lippe, Muenster, Germany, and the University of Muenster has ethically approved the study Characterisation of the Humoral Immune Response to SARS-CoV-2 in Vaccinees under the file number 2021-039-f-S. All study participants provided written informed consent.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData are available on reasonable request.